You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In an update medical policy, Anthem said it will cover the test every three years for certain patients for whom the test is considered medically necessary.
The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.
The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.